Annals of Hematology

, Volume 93, Issue 4, pp 683–692

An in-vitro assessment of tranexamic acid as an adjunct to rFVIII or rFVIIa treatment in haemophilia A

  • Catherine J. Rea
  • Jonathan H. Foley
  • David H. Bevan
  • Benny Sørensen
Original Article


Haemophilia is characterised by defective thrombin generation, reduced clot stability and spontaneous bleeding. Treatment with factor VIII (FVIII) concentrate or bypassing agents (e.g. recombinant factor VIIa (rFVIIa)) is generally effective. Occasionally, haemostasis is not achieved, which may reflect a failure of factor concentrate to normalise clot stability. Tranexamic acid (TXA) is often used to aid haemostasis in surgery (e.g. joint replacements and dental procedures). Used routinely as an adjunct, it may enhance clot stability and allow effective, reliable, and cost-effective treatment at lower doses of factor concentrate. This study hypothesised that clot stabilising adjunct TXA is required in addition to factor substitution to normalise clot stability in whole blood from patients with severe haemophilia A. The in vitro effect of varying concentrations of recombinant FVIII or recombinant FVIIa and adjunct TXA on whole blood clot stability was measured by thromboelastometry. Coagulation was triggered by tissue factor and clots were challenged with tissue plasminogen activator. The area under the elasticity curve was the primary endpoint. High concentrations of FVIII and rFVIIa increased clot stability to levels that were not significantly different from controls (Mean ± SD: control 112,694 ± 84,115; FVIII 78,662 ± 74,126; rFVIIa 95,918 ± 88,492). However, the response was highly variable between individuals and demonstrates why some patients show clinical resistance to treatment. Addition of TXA resulted in normalised clot stability in all individuals, even when combined with the lowest doses of factor concentrate. The results support the concept that a more efficient, reliable and cost effective treatment may be obtained if TXA is combined with factor concentrates to treat individuals with haemophilia.


Tranexamic acid Haemophilia A Clot stability Adjunct rFVIII rFVIIa 


  1. 1.
    Bolton-Maggs PH, Pasi KJ (2003) Haemophilias A and B Lancet 361:1801–1809. doi:10.1016/S0140-6736(03)13405-8 CrossRefGoogle Scholar
  2. 2.
    Mann KG, Brummel K, Butenas S (2003) What is all that thrombin for? J Thromb Haemost 1:1504–1514PubMedCrossRefGoogle Scholar
  3. 3.
    Mann KG, Butenas S, Brummel K (2003) The dynamics of thrombin formation. Arterioscler Thromb Vasc Biol 23:17–25PubMedCrossRefGoogle Scholar
  4. 4.
    Brummel-Ziedins KE, Branda RF, Butenas S, Mann KG (2009) Discordant fibrin formation in hemophilia. J Thromb Haemost 7:825–832. doi:10.1111/j.1538-7836.2009.03306.x PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Foley JH, Nesheim ME, Rivard GE, Brummel-Ziedins KE (2012) Thrombin activatable fibrinolysis inhibitor activation and bleeding in haemophilia A. Haemophilia 18:e316–e322. doi:10.1111/j.1365-2516.2011.02648.x PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    Broze GJ Jr, Higuchi DA (1996) Coagulation-dependent inhibition of fibrinolysis: role of carboxypeptidase-U and the premature lysis of clots from hemophilic plasma. Blood 88:3815–3823PubMedGoogle Scholar
  7. 7.
    Blomback B, Carlsson K, Fatah K, Hessel B, Procyk R (1994) Fibrin in human plasma: gel architectures governed by rate and nature of fibrinogen activation. Thromb Res 75:521–538PubMedCrossRefGoogle Scholar
  8. 8.
    Wolberg AS (2007) Thrombin generation and fibrin clot structure. Blood Rev 21:131–142. doi:10.1016/j.blre.2006.11.001 PubMedCrossRefGoogle Scholar
  9. 9.
    Manco-Johnson MJ, Abshire TC, Shapiro AD, Riske B, Hacker MR, Kilcoyne R, Ingram JD, Manco-Johnson ML, Funk S, Jacobson L, Valentino LA, Hoots WK, Buchanan GR, DiMichele D, Recht M, Brown D, Leissinger C, Bleak S, Cohen A, Mathew P, Matsunaga A, Medeiros D, Nugent D, Thomas GA, Thompson AA, McRedmond K, Soucie JM, Austin H, Evatt BL, Evatt BL (2007) Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 357:535–544PubMedCrossRefGoogle Scholar
  10. 10.
    van den Berg HM, De Groot PH, Fischer K (2007) Phenotypic heterogeneity in severe hemophilia. J Thromb Haemost 5(Suppl 1):151–156. doi:10.1111/j.1538-7836.2007.02503.x PubMedCrossRefGoogle Scholar
  11. 11.
    Ahnström J, Berntorp E, Lindvall K, Björkman S (2004) A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia. Haemophilia 10(6):689–697PubMedCrossRefGoogle Scholar
  12. 12.
    Gouw SC, van der Bom JG, van den Berg Marijke H (2007) Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood 109:4648–4654. doi:10.1182/blood-2006-11-056291 PubMedCrossRefGoogle Scholar
  13. 13.
    Astermark J, Donfield SM, DiMichele DM, Gringeri A, Gilbert SA, Waters J, Berntorp E (2007) A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood 109:546–551. doi:10.1182/blood-2006-04-017988 PubMedCrossRefGoogle Scholar
  14. 14.
    Berntorp E (2009) Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors. Haemophilia 15:3–10. doi:10.1111/j.1365-2516.2008.01931.x PubMedCrossRefGoogle Scholar
  15. 15.
    Rea CJ, Foley JH, Ingerslev J, Sorensen B (2010) Factor XIII combined with recombinant factor VIIa: a new means of treating severe haemophilia A. J Thromb Haemost. doi:10.1111/j.1538-7836.2010.04171.x Google Scholar
  16. 16.
    Sorensen B, Persson E, Ingerslev J (2007) Factor VIIa analogue (V158D/E296V/M298Q-FVIIa) normalises clot formation in whole blood from patients with severe haemophilia A. Br J Haematol 137:158–165. doi:10.1111/j.1365-2141.2007.06534.x PubMedCrossRefGoogle Scholar
  17. 17.
    Santagostino E, Mancuso ME, Rocino A, Mancuso G, Scaraggi F, Mannucci PM (2006) A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors. J Thromb Haemost 4:367–371. doi:10.1111/j.1538-7836.2006.01772.x PubMedCrossRefGoogle Scholar
  18. 18.
    Ingerslev J, Sorensen B (2011) Parallel use of by-passing agents in haemophilia with inhibitors: a critical review. Br J Haematol 155:256–262. doi:10.1111/j.1365-2141.2011.08854.x PubMedCrossRefGoogle Scholar
  19. 19.
    Rea CJ, Foley JH, Sorensen B (2012) Factor XIII in the treatment of hemophilia A. N Engl J Med 366:281–283. doi:10.1056/NEJMc1113270 PubMedCrossRefGoogle Scholar
  20. 20.
    Foley JH, Petersen KU, Rea CJ, Harpell L, Powell S, Lillicrap D, Nesheim ME, Sorensen B (2012) Solulin increases clot stability in whole blood from individuals and dogs with hemophilia. Blood. doi:10.1182/blood-2011-11-392308 Google Scholar
  21. 21.
    Hvas AM, Sorensen HT, Norengaard L, Christiansen K, Ingerslev J, Sorensen B (2007) Tranexamic acid combined with recombinant factor VIII increases clot resistance to accelerated fibrinolysis in severe hemophilia. A J Thromb Haemost 5:2408–2414. doi:10.1111/j.1538-7836.2007.02755.x CrossRefGoogle Scholar
  22. 22.
    Schulman S, Loogna J, Wallensten R (2004) Minimizing factor requirements for surgery without increased risk. Haemophilia 10(Suppl 4):35–40. doi:10.1111/j.1365-2516.2004.01041.x PubMedGoogle Scholar
  23. 23.
    Zanon E, Martinelli F, Bacci C, Zerbinati P, Girolami A (2000) Proposal of a standard approach to dental extraction in haemophilia patients. A case–control study with good results. Haemophilia 6:533–536PubMedCrossRefGoogle Scholar
  24. 24.
    Beyer R, Ingerslev J, Sorensen B (2010) Current practice in the management of muscle haematomas in patients with severe haemophilia. Haemophilia 16:926–931. doi:10.1111/j.1365-2516.2010.02275.x PubMedCrossRefGoogle Scholar
  25. 25.
    Grassin-Delyle S, Tremey B, Abe E, Fischler M, Alvarez JC, Devillier P, Urien S (2013) Population pharmacokinetics of tranexamic acid in adults undergoing cardiac surgery with cardiopulmonary bypass. Br J Anaesth. doi:10.1093/bja/aet255 PubMedGoogle Scholar
  26. 26.
    Sorensen B, Johansen P, Christiansen K, Woelke M, Ingerslev J (2003) Whole blood coagulation thrombelastographic profiles employing minimal tissue factor activation. J Thromb Haemost 1:551–558PubMedCrossRefGoogle Scholar
  27. 27.
    Hemker HC, Giesen P, Al Dieri R, Regnault V, de Smedt E, Wagenvoord R, Lecompte T, Beguin S (2003) Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 33:4–15PubMedCrossRefGoogle Scholar
  28. 28.
    Young G, Ebbesen LS, Viuff D, Di Paola J, Konkle BA, Negrier C, Pasi J, Ingerslev J (2008) Evaluation of thromboelastography for monitoring recombinant activated factor VII ex vivo in haemophilia A and B patients with inhibitors: a multicentre trial. Blood Coagul Fibrinolysis 19:276–282. doi:10.1097/MBC.0b013e3283001cdc00001721-200806000-00004 PubMedCrossRefGoogle Scholar
  29. 29.
    de Vries C, Veerman H, Pannekoek H (1989) Identification of the domains of tissue-type plasminogen activator involved in the augmented binding to fibrin after limited digestion with plasmin. J Biol Chem 264:12604–12610PubMedGoogle Scholar
  30. 30.
    Silva MM, Thelwell C, Williams SC, Longstaff C (2012) Regulation of fibrinolysis by C-terminal lysines operates through plasminogen and plasmin but not tissue plasminogen activator (tPA). J Thromb Haemost. doi:10.1111/j.1538-7836.2012.04925.x PubMedGoogle Scholar
  31. 31.
    Rand MD, Lock JB, van’t Veer C, Gaffney DP, Mann KG (1996) Blood clotting in minimally altered whole blood. Blood 88:3432–3445PubMedGoogle Scholar
  32. 32.
    Larsen OH, Ezban M, Persson E, Ingerslev J, Sorensen B (2010) Artificial contact pathway activation masks the haemostatic potential of rFVIIa and NN1731 in thrombocytopenic whole blood. Br J Haematol 150:124–127. doi:10.1111/j.1365-2141.2010.08170.x PubMedGoogle Scholar
  33. 33.
    Ninivaggi M, Dargaud Y, van Oerle R, de Laat B, Hemker HC, Lindhout T (2011) Thrombin generation assay using factor IXa as a trigger to quantify accurately factor VIII levels in haemophilia A. J Thromb Haemost 9:1549–1555. doi:10.1111/j.1538-7836.2011.04358.x PubMedCrossRefGoogle Scholar
  34. 34.
    Dargaud Y, Lienhart A, Meunier S, Hequet O, Chamouard V, Marin S, Negrier C (2005) Major surgery in a severe haemophilia A patient with high titre inhibitor: use of the thrombin generation test in the therapeutic decision. Haemophilia 11:552–558. doi:10.1111/j.1365-2516.2005.01141.x PubMedCrossRefGoogle Scholar
  35. 35.
    Ingram GI, Inglish PJ, Bennett AE (1972) Tranexamic acid for prophylaxis in haemophilia. J Clin Pathol 25:629PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Catherine J. Rea
    • 1
    • 2
  • Jonathan H. Foley
    • 4
  • David H. Bevan
    • 1
  • Benny Sørensen
    • 3
  1. 1.Centre for Haemophilia and ThrombosisGuy’s and St Thomas’ NHS Foundation TrustLondonUK
  2. 2.School of MedicineKing’s College LondonLondonUK
  3. 3.Centre for Haemophilia and ThrombosisAarhus University HospitalSkejbyDenmark
  4. 4.Centre for Blood ResearchUniversity of British ColumbiaVancouverCanada

Personalised recommendations